Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 5Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 73Nivolumab 27atezolizumab 15Docetaxel 10Cyclophosphamide 10cemiplimab 9Ipilimumab 9Paclitaxel 8Interleukin-2 8Biopsy 7fludarabine 6durvalumab 6avelumab 6Taxes 6Specimen Handling 6epacadostat 5Magnetic Resonance Spectroscopy 5Immune Checkpoint Inhibitors 5Gemcitabine 5Drug Therapy 5Cisplatin 5Carboplatin 5spartalizumab 4Radiotherapy 4Radiosurgery 4Pemetrexed 4Cetuximab 4utomilumab 3trametinib 3poly ICLC 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × sotigalimab × Head & Neck × Clear all
NCT02482168 2023-12-20

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Apexigen America, Inc.

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡